Phillip Jamarr Flippen, LMHP-R Counselor - Addiction (Substance Use Disorder) Medicare: Medicare Enrolled Practice Location: 278 Maya Ln, Ringgold, VA 24586 Phone: 434-630-8494 Fax: 888-767-7937 |
News Archive
MediciNova Inc, a biopharmaceutical company publicly traded on the NASDAQ Global Market and the Hercules Market of the Osaka Securities Exchange (Code Number:4875), today reported that the June 22, 2010 issue of Proceedings of the National Academy of Sciences USA included an article related to the mechanism of action of MN-166 (ibudilast), as an emerging therapeutic for neurological disorders.
Immune Network Ltd. advises that Ukrainian company Ekomed LLC has agreed to collaborate with Immune Network and Immunitor for further clinical research of a tableted form of Ekomed's well-known immunomodulator herbal product Immunoxel/Dzherelo.
A team of scientists from A-Alpha Bio., USA, has recently conducted a large-scale screening of 33 therapeutic antibodies to examine their binding affinity to a number of SARS-CoV-2 variants. The team analyzed the impact of potential mutations in the spike RBD on antibody efficacy.
Physicians in their medical residency training programs often focus on scientific reasoning and research evidence in their efforts to provide medical care. While appropriate, this focus may overshadow subtle and indirect communication that reveals important information about the patient's experience with their illness that will help the physician provide better care.
Using high-resolution functional MRI imaging in patients with Alzheimer's disease and in mouse models of the disease, Columbia University Medical Center researchers have clarified three fundamental issues about Alzheimer's: where it starts, why it starts there, and how it spreads. In addition to advancing understanding of Alzheimer's, the findings could improve early detection of the disease, when drugs may be most effective.
› Verified 7 days ago